STEINACH, Switzerland, Feb. 17, 2025 /PRNewswire/ — On Tuesday, March 11, IQAir will release its highly anticipated 7th annual World Air Quality Report, offering an in-depth analysis of global air pollution trends in 2024. With air pollution remaining the single greatest threat to human and environmental health, this report will uncover troubling new insights about PM2.5 air pollution worldwide.
WHAT: IQAir’s 7th annual World Air Quality Report presents a detailed global air pollution analysis, tracking exposure to harmful PM2.5 air pollution across 138 countries, territories, and regions, spanning 8,956 locations. The report is based on data from more than 40,000 air quality monitoring stations worldwide, offering the most comprehensive snapshot of global air pollution to date.
WHEN: The 2024 World Air Quality Report will be publicly released on Tuesday, March 11, at 12:01 a.m. Eastern Time (04:00 UTC). Credentialed journalists can request embargoed access to the report and interviews ahead of the release.
WHY: IQAir’s latest findings reveal millions of people continue to breathe polluted air, endangering their health and well-being. The 2024 World Air Quality Report will analyze:
WHERE: The full 2024 World Air Quality Report will be available at www.iqair.com/us after the embargo lifts. Embargoed findings and interviews can be requested before the official release.
WHO: The following are available for media interviews on report findings and health impacts of air pollution:
HOW: To request embargoed report findings or an embargoed interview, contact Armen Araradian at pr.na@iqair.com.
ABOUT IQAir:
IQAir is a Swiss technology company that empowers individuals, organizations, and governments to improve air quality through information, collaboration, and intervention.
For press inquiries, interviews, and media coverage please contact:
Armen Araradian
pr.na@iqair.com
+1 (562) 315-6010
SOURCE IQAir
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…